BH 4 -responsive hyperphenylalaninaemia (HPA) is a recently described variant of phenylalanine hydroxylase (PAH) deficiency caused by specific mutations in the PAH gene. Diagnosis is performed by the tetrahydrobiopterin (BH 4 ) loading test (20 mg/kg body weight) and the overall prevalence of BH 4 -responsiveness within patients with phenylketonuria (PKU) for blood phenylalanine reduction of 20%, 30%, 40% and 50% was found to be 48%, 38%, 31% and 24%, respectively, 8 h after the administration, and 55%, 46%, 41% and 33%, respectively, 24 h after the administration. Using the standard 30% cut-off, BH 4 -responsiveness was similar regardless of the two modalities in patients with mild hyperphenylalaninaemia (79-83% responders), mild PKU (49-60% responders), and classical PKU (7-10% responders). About 46% of all HPA patients were responders 24 h post loading (Fiege and Blau 2007) . BH 4 (drug name Kuvan or Sapropterin) is registered in the USA (FDA) and is currently under preregistration in Europe (EMEA) (Burnett 2007) .
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A number of publications have documented that a 24-hour protocol with 20 mg/kg BH 4 is the most commonly used method and that multiple administrations of BH 4 and extension of the test to up to one week may detect some additional Fslow_ responders. However, some authors use lower doses of BH 4 (10 mg/kg) or a combination of phenylalanine (100 mg/kg) and BH 4 (20 mg/kg), and some authors monitor blood phenylalanine levels after repeated administration of BH 4 over a period of up to two weeks. In addition, some of the loading test experiments are performed under dietary supplementation with a low-phenylalanine food. This may result in a relative high number of initially positive responders (>50%) who did not respond to a long-term treatment, as documented by a recent multicentre study (Levy et al 2007) .
In this issue of the Journal (pp. 67-72), U. Langenbeck proposes another approach for the classification of BH 4 -responsiveness. He calculated the half-life (t 1/2 ) of blood phenylalanine at different time points following BH 4 administration. Using a log-linear regression, he compared data from several published reports with the model of a single exponential decay (SED) of blood phenylalanine. The conclusion is that only during the first 15 h after BH 4 administration does the kinetic behaviour of plasma phenylalanine obey first-order kinetics and that, with a test duration of 24 h, compatibility with the SED model is only partial. Indeed, Fiege and Blau (2007) observed that 2.7% of patients in whom the loading test was performed over 24 h were defined as responders only at 8 h. Also, 8.8% of patients were responders at 24 h, but not at 8 h. In about 15% of all patients who responded to BH 4 by 20%, blood phenylalanine levels increased from 8 h to 24 h by at least 10%. Accordingly, they suggest that the BH 4 loading test should be modified to include a second administration of 10-20 mg/kg BH 4 at time 12 h and assessment of plasma phenylalanine levels at times 0, 8, 12 and 24 h after BH 4 administrations. Thus, additional investigations are necessary in order to evaluate the importance of the 12-or 15-hour blood phenylalanine values. Long-term (1-2 weeks) loading tests are more expensive and definitely not practical for the initial screening.
Langenbeck further suggests in his article that genotype-phenotype analysis may benefit from the t 1/2 -driven diagnostic approach and that knowledge of individual t 1/2 values and age-specific protein synthesis could improve therapeutic decisions. Data from the BIOPKU database demonstrate that the genotypepredicted BH 4 -responsiveness is on average higher than that obtained from the BH 4 loading test and that the patient_s genotype may certainly exclude nonresponsiveness and to some extent predict a potential responder (Zurflü h et al 2008) . A combination of the BH 4 loading test and genotype analysis together with the phenylalanine kinetics (t 1/2 ) may certainly improve the definition of the BH 4 -responsiveness.
On the basis of present knowledge, guidelines for the definition of BH 4 -responsiveness should include the following investigations: (1) Single loading test with BH 4 (20 mg/kg) and monitoring of blood phenylalanine at 0, 8, 12 (15) , and 24 h. (2) Reduction of blood phenylalanine levels of >20-30% as an indicator for a trial with BH 4 (initial doses of 10 mg/kg) over several weeks. (3) Titration of the individual BH 4 requirement (5-20 mg/kg) to maintain optimal blood phenylalanine levels. (4) Determination of the daily phenylalanine tolerance. (5) Genotyping.
